Aptevo Therapeutics Inc. (APVO)
NASDAQ: APVO · Real-Time Price · USD
2.000
-0.040 (-1.96%)
Aug 15, 2025, 9:51 AM - Market open
Aptevo Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
37
Market Cap
6.58M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
APVO News
- 2 days ago - Aptevo Highlights APVO442, a CD3-Directed Preclinical Candidate for Prostate Cancer - Accesswire
- 4 days ago - Aptevo Therapeutics Reports 2Q25 Financial Results And Provides A Business Update - Accesswire
- 7 weeks ago - Aptevo Therapeutics Announces Closing of $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire
- 2 months ago - Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers - Accesswire
- 2 months ago - Smith & Wesson Brands Posts Weak Q4 Results, Joins Aptevo Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
- 2 months ago - Aptevo More Than Doubles After Favorable Results in Leukemia Study - Market Watch
- 2 months ago - Aptevo Therapeutics Touts Data From Investigational Drug Trial For Aggressive Blood Cancer - Benzinga
- 2 months ago - Aptevo Therapeutics Announces $8 Million Offering Priced At-the-Market Under Nasdaq Rules - Accesswire